Posaconazole: 3 Key Uses, Dosing, And Side Effects
Comprehensive guide to posaconazole, a broad-spectrum triazole antifungal for treating invasive fungal infections in immunocompromised patients.
Posaconazole is a triazole antifungal medication primarily used to prevent and treat serious invasive fungal infections in patients with weakened immune systems, such as those undergoing hematopoietic stem cell transplants or chemotherapy for hematologic malignancies. It demonstrates broad-spectrum activity against yeasts like Candida species and molds including Aspergillus and zygomycetes, making it valuable for prophylaxis and salvage therapy in refractory cases.
What is posaconazole?
Posaconazole, marketed under brand names such as Noxafil, Posaconazole AHCL, and Posanol, belongs to the triazole class of antifungals. Structurally related to itraconazole, it was developed to address limitations of earlier azoles, offering enhanced activity against resistant fungi and better oral bioavailability when taken with food. Approved by regulatory bodies like the FDA and EMA, it is indicated for adults and patients aged 13 years and older at high risk of invasive fungal infections (IFIs). Unlike fluconazole, which has narrower coverage, posaconazole inhibits a wider range of pathogens, including those causing life-threatening infections in immunocompromised hosts.
Who gets fungal infections?
Invasive fungal infections predominantly affect immunocompromised individuals, including those with hematologic malignancies, prolonged neutropenia from chemotherapy, hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), and solid organ transplant patients. High-risk groups also encompass patients with advanced AIDS, those receiving high-dose corticosteroids, or individuals with chronic granulomatous disease. Fungi such as Aspergillus fumigatus, Candida albicans, and zygomycetes thrive in these settings due to impaired neutrophil function and mucosal barriers, leading to high mortality rates if untreated—often exceeding 50% for invasive aspergillosis.
- Hematologic malignancy patients with prolonged neutropenia (>7 days).
- HSCT recipients, especially with GVHD on immunosuppressive therapy.
- Solid organ transplant patients, particularly lung or liver recipients.
- Critically ill ICU patients with central lines or broad-spectrum antibiotics.
Prevention of invasive fungal infections
Posaconazole is FDA-approved for prophylaxis against invasive Aspergillus and Candida infections in high-risk patients aged 13 and older. Randomized trials demonstrated its superiority over fluconazole in preventing IFIs, with a 200 mg three times daily oral suspension dose achieving proven efficacy in HSCT and neutropenic patients. In one double-blind study, posaconazole reduced IFI incidence to 2% versus 8% with fluconazole, particularly against molds. EMA approvals extend its prophylactic use in blood cancer and HSCT settings.
Treatment
Posaconazole serves as salvage therapy for invasive aspergillosis, fusariosis, zygomycosis, chromoblastomycosis, and coccidioidomycosis refractory to or intolerant of amphotericin B, itraconazole, or fluconazole. For oropharyngeal candidiasis (OPC), including cases refractory to itraconazole/fluconazole, it is a first-line option, especially in severe or immunocompromised patients. Clinical success rates reach 79% in zygomycosis salvage therapy at 800 mg/day, with 83% response in Rhizopus and Mucor species. It treats invasive aspergillosis when other agents fail.
Clinical use in dermatology
In dermatology, posaconazole is employed off-label for refractory deep fungal infections with cutaneous manifestations, such as phaeohyphomycosis, chromoblastomycosis, mycetoma, and sporotrichosis. Zygomycosis (mucormycosis) often presents with necrotic skin lesions in diabetics or immunocompromised patients, responding to posaconazole salvage therapy. Coccidioidomycosis dissemination to skin responds when azoles fail. Its broad spectrum covers dematiaceous molds causing subcutaneous infections. Case series report success in cutaneous fusariosis and alternariosis refractory to voriconazole.
Dose and administration
Posaconazole is available as oral suspension (40 mg/mL), delayed-release tablets (100 mg), and delayed-release oral suspension. Administration requires high-fat meals or acidic beverages to optimize absorption, as bioavailability increases 4-fold with food.
| Indication | Dose | Formulation | Notes |
|---|---|---|---|
| Prophylaxis of IFIs | 200 mg three times daily | Oral suspension or delayed-release tablets | With food; continue through high-risk period |
| OPC (initial/refractory) | 100 mg twice daily for 1 day, then 100 mg once daily for 13 days | Oral suspension | Swish and swallow |
| Salvage therapy (invasive infections) | 400 mg twice daily or 200 mg four times daily | Oral suspension/tablets | Total 800 mg/day with food; duration 4-12 weeks or longer |
Monitor plasma levels (target >0.7 mg/L) in salvage therapy due to variable pharmacokinetics. Adjust for renal/hepatic impairment; no IV formulation widely available.
Pharmacology
Mechanism of action
Posaconazole selectively inhibits fungal lanosterol 14α-demethylase (CYP51), blocking ergosterol biosynthesis—a critical fungal cell membrane sterol. This causes accumulation of toxic methylated sterols, disrupting membrane integrity, inhibiting growth, and leading to fungal cell death. It exhibits lower MICs than itraconazole against Aspergillus and zygomycetes.
- Broad spectrum: Candida spp. (including C. krusei, C. glabrata), Aspergillus spp., Cryptococcus neoformans, zygomycetes (Mucor, Rhizopus), Fusarium, Scedosporium.
- Resistance: Rare; mediated by CYP51 mutations or efflux pumps.
Monitoring
Therapeutic drug monitoring (TDM) is recommended for treatment indications, targeting trough levels >1.0 mg/L (prophylaxis >0.5 mg/L) to ensure efficacy and minimize resistance. Weekly liver function tests (LFTs) due to hepatotoxicity risk; ECG for QT prolongation; serum creatinine for renal effects. Monitor for drug interactions via CYP3A4 inhibition.
Side effects
Common adverse effects (incidence >10%) include diarrhea (26%), nausea (26%), fever (22%), vomiting (12%), and headache. Serious risks encompass hepatotoxicity (elevated ALT/AST in 15-20%), QT prolongation, hypokalemia, and rare adrenal insufficiency. Mucosal inflammation and rash occur in 5-10%. Discontinuation due to AEs is ~10%.
- Gastrointestinal: Nausea, diarrhea, abdominal pain.
- Hepatic: Cholestasis, hepatitis (monitor LFTs).
- Cardiac: QTc prolongation (avoid with other QT-prolongers).
- Metabolic: Hypokalemia, mucositis.
Interactions with other drugs
As a potent CYP3A4 inhibitor, posaconazole increases levels of tacrolimus (dose reduce 1/3), cyclosporine (reduce 1/3), sirolimus (contraindicated), and HMG-CoA reductase inhibitors (rhabdomyolysis risk). Proton pump inhibitors (e.g., omeprazole) reduce absorption by raising gastric pH—avoid or separate. Inducers like rifampin, phenytoin decrease posaconazole levels.
| Drug Class | Interaction | Management |
|---|---|---|
| Calcineurin inhibitors | ↑ levels (tacrolimus AUC x4) | Frequent TDM, dose reduction |
| PPIs/H2 blockers | ↓ posaconazole absorption | Avoid; use H2 blockers if necessary | Strong CYP3A4 inducers | ↓ posaconazole levels | Avoid (rifabutin, rifampin) |
Alternatives to posaconazole
Alternatives vary by indication:
- Prophylaxis: Voriconazole, isavuconazole, liposomal amphotericin B.
- Invasive aspergillosis: Voriconazole (first-line), isavuconazole, amphotericin B.
- Candidiasis: Echinocandins (caspofungin), fluconazole.
- Zygomycosis: Liposomal amphotericin B + surgery.
Frequently asked questions (FAQs)
Q: What is posaconazole used for?
A: Primarily for preventing invasive Aspergillus and Candida infections in high-risk immunocompromised patients and treating refractory OPC, aspergillosis, and other invasive mycoses.
Q: How should posaconazole be taken?
A: With high-fat meals for optimal absorption; 200 mg TID for prophylaxis, 800 mg/day divided for treatment.
Q: Is drug monitoring required?
A: Yes, for treatment; target trough >1.0 mg/L to correlate with outcomes.
Q: What are common side effects?
A: Nausea, diarrhea, fever, vomiting, headache; monitor LFTs and electrolytes.
Q: Can posaconazole be used in children?
A: Approved for ≥13 years in prophylaxis; limited data younger.
Q: Is posaconazole effective against zygomycetes?
A: Yes, salvage therapy shows 79% response rate.
References
- Posaconazole: Uses, Interactions, Mechanism of Action — DrugBank Online. 2023. https://go.drugbank.com/drugs/DB01263
- Posaconazole (Noxafil): a new triazole antifungal agent — PMC (NCBI). 2007-04-13. https://pmc.ncbi.nlm.nih.gov/articles/PMC1849883/
- Posaconazole — Wikipedia. 2023. https://en.wikipedia.org/wiki/Posaconazole
- Posaconazole AHCL — European Medicines Agency (EMA). 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl
- Posaconazole (oral route) — Mayo Clinic. 2023. https://www.mayoclinic.org/drugs-supplements/posaconazole-oral-route/description/drg-20069121
- Posaconazole (Noxafil) — WebMD. 2023. https://www.webmd.com/drugs/posaconazole-noxafil
- Noxafil (posaconazole) Label — FDA. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf
- Posaconazole — LiverTox (NCBI Bookshelf). 2020-05-01. https://www.ncbi.nlm.nih.gov/books/NBK548934/
Similar Articles
Read full bio of Sneha Tete
